Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

Published:2007-03-29 Issue:1 Volume:61 Page:113-123
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Vassal G.,Michel G.,Espérou H.,Gentet J. C.,Valteau-Couanet D.,Doz F.,Mechinaud F.,Galambrun C.,Neven B.,Zouabi H.,Nguyen L.,Puozzo C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-007-0455-2.pdf

Reference54 articles.

1. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8(3):145–154

2. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia Biol Blood Marrow Transplant 8(9):477–485

3. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DSL, et al (2000) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclosphosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6:548–554

4. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, et al (2001) Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 28(8):743–751

5. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, et al (2001) Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 28(11):1013–1018

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia;Pediatric Blood & Cancer;2024-01-12

2. Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen;Bone Marrow Transplantation;2023-03-31

3. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2023-02-01

4. Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen.;2023-01-30

5. Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring;Bone Marrow Transplantation;2022-01-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3